Multivariate analysis of chronic GVHD according to NIH criteria in the BM/PB cohort
| Risk factors . | Moderate/Severe . | Severe . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Acute GVHD | ||||
| None | Reference | 1.0 | Reference | 1.0 |
| Grade 1 | 0.93 (0.74-1.18) | .57 | 1.18 (0.80-1.72) | .41 |
| Grade 2 | 1.53 (1.25-1.88) | <.001 | 1.55 (1.09-2.21) | .014 |
| Grade 3-4 | 1.94 (1.49-2.53) | <.001 | 2.65 (1.76-3.98) | <.001 |
| Age | ||||
| ≤56 y | 1.16 (0.95-1.42) | .14 | 1.25 (0.90-1.73) | .18 |
| 36-55 y | Reference | 1.0 | Reference | 1.0 |
| 16-35 y | 0.90 (0.70-1.15) | .40 | 1.06 (0.71-1.58) | .76 |
| Sex mismatch | ||||
| Match or male-to-female | Reference | 1.0 | Reference | 1.0 |
| Female-to-male | 1.14 (0.93-1.40) | .21 | 1.04 (0.73-1.47) | .83 |
| Disease risk index | ||||
| Low | Reference | 1.0 | Reference | 1.0 |
| Intermediate | 0.87 (0.63-1.20) | .39 | 0.93 (0.54-1.58) | .78 |
| High | 0.84 (0.59-1.18) | .31 | 0.93 (0.52-1.66) | .81 |
| Very high | 0.68 (0.37-1.22) | .19 | 1.39 (0.62-3.11) | .43 |
| HCT-CI | ||||
| 0-1 | Reference | 1.0 | Reference | 1.0 |
| ≥2 | 1.03 (0.85-1.25) | .77 | 1.06 (0.78-1.46) | .70 |
| Donor type | ||||
| Matched related | Reference | 1.0 | Reference | 1.0 |
| Matched unrelated | 1.16 (0.87-1.55) | .31 | 1.77 (1.10-2.86) | .020 |
| Mismatched unrelated | 1.19 (0.86-1.65) | .29 | 1.82 (1.06-3.13) | .031 |
| 1-locus MMRD | 0.74 (0.34-1.59) | .44 | 1.11 (0.34-3.66) | .86 |
| Haploidentical | 0.63 (0.47-0.86) | .0038 | 0.75 (0.44-1.25) | .27 |
| Donor source | ||||
| BM | Reference | 1.0 | Reference | 1.0 |
| PB | 1.33 (1.07-1.64) | .010 | 1.76 (1.24-2.50) | .0016 |
| Conditioning regimen | ||||
| MAC | Reference | 1.0 | Reference | 1.0 |
| RIC | 0.91 (0.75-1.11) | .36 | 0.88 (0.64-1.22) | .45 |
| GVHD prophylaxis | ||||
| CsA based | Reference | 1.0 | Reference | 1.0 |
| TAC based | 1.00 (0.77-1.29) | .97 | 0.99 (0.64-1.54) | .97 |
| In vivo T-cell depletion | ||||
| No | Reference | 1.0 | Reference | 1.0 |
| Yes | 0.77 (0.6-0.99) | .039 | 0.41 (0.25-0.67) | <.001 |
| Risk factors . | Moderate/Severe . | Severe . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Acute GVHD | ||||
| None | Reference | 1.0 | Reference | 1.0 |
| Grade 1 | 0.93 (0.74-1.18) | .57 | 1.18 (0.80-1.72) | .41 |
| Grade 2 | 1.53 (1.25-1.88) | <.001 | 1.55 (1.09-2.21) | .014 |
| Grade 3-4 | 1.94 (1.49-2.53) | <.001 | 2.65 (1.76-3.98) | <.001 |
| Age | ||||
| ≤56 y | 1.16 (0.95-1.42) | .14 | 1.25 (0.90-1.73) | .18 |
| 36-55 y | Reference | 1.0 | Reference | 1.0 |
| 16-35 y | 0.90 (0.70-1.15) | .40 | 1.06 (0.71-1.58) | .76 |
| Sex mismatch | ||||
| Match or male-to-female | Reference | 1.0 | Reference | 1.0 |
| Female-to-male | 1.14 (0.93-1.40) | .21 | 1.04 (0.73-1.47) | .83 |
| Disease risk index | ||||
| Low | Reference | 1.0 | Reference | 1.0 |
| Intermediate | 0.87 (0.63-1.20) | .39 | 0.93 (0.54-1.58) | .78 |
| High | 0.84 (0.59-1.18) | .31 | 0.93 (0.52-1.66) | .81 |
| Very high | 0.68 (0.37-1.22) | .19 | 1.39 (0.62-3.11) | .43 |
| HCT-CI | ||||
| 0-1 | Reference | 1.0 | Reference | 1.0 |
| ≥2 | 1.03 (0.85-1.25) | .77 | 1.06 (0.78-1.46) | .70 |
| Donor type | ||||
| Matched related | Reference | 1.0 | Reference | 1.0 |
| Matched unrelated | 1.16 (0.87-1.55) | .31 | 1.77 (1.10-2.86) | .020 |
| Mismatched unrelated | 1.19 (0.86-1.65) | .29 | 1.82 (1.06-3.13) | .031 |
| 1-locus MMRD | 0.74 (0.34-1.59) | .44 | 1.11 (0.34-3.66) | .86 |
| Haploidentical | 0.63 (0.47-0.86) | .0038 | 0.75 (0.44-1.25) | .27 |
| Donor source | ||||
| BM | Reference | 1.0 | Reference | 1.0 |
| PB | 1.33 (1.07-1.64) | .010 | 1.76 (1.24-2.50) | .0016 |
| Conditioning regimen | ||||
| MAC | Reference | 1.0 | Reference | 1.0 |
| RIC | 0.91 (0.75-1.11) | .36 | 0.88 (0.64-1.22) | .45 |
| GVHD prophylaxis | ||||
| CsA based | Reference | 1.0 | Reference | 1.0 |
| TAC based | 1.00 (0.77-1.29) | .97 | 0.99 (0.64-1.54) | .97 |
| In vivo T-cell depletion | ||||
| No | Reference | 1.0 | Reference | 1.0 |
| Yes | 0.77 (0.6-0.99) | .039 | 0.41 (0.25-0.67) | <.001 |
Abbreviations are explained in Table 1.